# UHS EXIT ANALYSIS â€” Pre-Earnings Feb 25, 2026

**Date:** 2026-02-13
**Analyst:** Review Agent (Framework v4.0)
**Position:** 2 shares | Invested $402.84 | Avg Cost $201.42
**Current Price:** $234.05 | P&L: +$65.26 (+16.2%)
**Fair Value (v3.0):** $213 | **MoS: -9.0% (OVERVALUED)**
**Quality Score:** Tool 60 (legacy) / Profile-assessed 51 | Tier C
**Conviction:** LOW | Status: ON PROBATION

---

## EXIT PROTOCOL: 6-GATE ANALYSIS

### GATE 1: Kill Condition Activated?

**RESULT: NO kill condition TRIGGERED yet, but MULTIPLE approaching.**

| KC# | Condition | Status | Assessment |
|-----|-----------|--------|------------|
| KC#1 | ROIC < WACC for 2 consecutive quarters | **WATCH** | ROIC 10.8%, WACC 9.3%, spread only 1.5pp. One bad quarter erases the buffer. FY2024 data shows 6.6% ROIC in 2022 (below WACC). |
| KC#2 | Dividend cut or suspension | OK | Dividend maintained, announced recently |
| KC#3 | New DOJ/OIG investigation | OK | Existing 5-year CIA is active but no new investigation |
| KC#4 | Behavioral health volume decline >5% YoY | **WATCH** | Q1 2025 DECLINED, Q2 +0.4%, Q3 +0.5%. Pattern is near-zero growth, not the 7-9% thesis projected |
| KC#5 | FY2026 EPS guidance <$20.00 | **CHECK Feb 25** | This is the binary event. Medicaid cuts (OBBBA) could force conservative guidance |
| KC#6 | Goodwill impairment >$500M | OK | $3.93B/$6.76B = 58% of equity. No impairment yet |
| KC#7 | Operating costs/revenue >97% | OK | Currently ~88% |
| KC#8 | Telehealth/AI disrupts behavioral >10% | MONITOR | No near-term trigger |
| KC#9 | Single-payer rate setting legislation | MONITOR | Not imminent |

**Assessment:** No kill condition is technically triggered. However, KC#1 (ROIC near WACC) is structurally fragile, KC#4 (behavioral volumes) shows a deteriorating pattern, and KC#5 (FY2026 guidance) is the key binary risk on Feb 25.

---

### GATE 2: Thesis Still Valid?

**RESULT: SIGNIFICANTLY DEBILITATED. 3 of 4 original contra-theses have weakened.**

**Original thesis (Feb 2, 2026):**
1. Behavioral health secular growth 7-9% CAGR --> **CONTRADICTED.** Q1 declined, Q2 +0.4%, Q3 +0.5%. Revenue growth is pricing-driven, not volume-driven.
2. ACA/Medicaid deeply embedded, safe from cuts --> **WRONG.** OBBBA signed July 4, 2025. $1T Medicaid cuts are LAW. 11.8M lose coverage. UHS loses estimated $360-400M/yr by 2032.
3. ROIC improving trajectory --> **STALLED.** 10.8% ROIC vs 9.3% WACC = 1.5pp spread. Was 6.6% in 2022. No trend of widening.
4. Labor cost normalization --> **PARTIALLY CORRECT.** Margins recovering. But FY2025 may be peak.

**Thesis validity: DEBILITATED, approaching INVALIDATED.**

CEO Marc Miller himself acknowledged OBBBA "simply can't be left as is" -- signaling even management sees this as a structural problem they hope will be politically modified. That is a HOPE, not a thesis.

---

### GATE 3: Current MoS

**RESULT: MoS is NEGATIVE. The position is OVERVALUED.**

| Metric | Value |
|--------|-------|
| Current Price | $234.05 |
| Fair Value (v3.0, risk-adjusted) | $213 |
| MoS | **-9.0%** |
| Bear Case FV | $190 |
| Downside to Bear | -18.8% (-$88) |
| Base Case FV | $231 |
| Bull Case FV | $276 |

**Reasoning:** At $234.05, UHS trades ABOVE every probability-weighted fair value estimate:
- 9% above risk-adjusted FV ($213)
- 1.3% above base case blended ($231)
- Only below bull case ($276), which requires FY2026 guide >$23 + behavioral volume acceleration

Since our v3.0 analysis on Feb 10 when price was $212.94 (approximately at FV), the stock has risen 10% WITH NO NEW POSITIVE INFORMATION. This makes the position even less attractive.

**Precedent check (decisions_log.yaml):**
- PFE was sold at MoS -3.2% (overvalued near 52w high). UHS is now MORE overvalued at -9%.
- SAN.PA was sold at MoS ~0%. UHS is now MORE overvalued.
- IMB.L was sold at MoS -14.6%. UHS is approaching similar territory.
- SHEL.L was sold at MoS -3.5%. UHS is more overvalued than SHEL.L was.

**Every precedent of negative MoS in our portfolio resulted in SELL.** There are ZERO precedents of holding a Tier C position with negative MoS.

---

### GATE 4: Better Opportunity? (Opportunity Score)

**RESULT: Dramatically better opportunities exist in pipeline.**

**Opportunity Score vs Pipeline Candidates:**

| Candidate | QS | Tier | MoS at Entry | Pipeline Status | OS Formula |
|-----------|-----|------|-------------|-----------------|------------|
| ROP | 70 adj | B (upper) | 22% at $300 | R4 complete, standing order | OS = (22/-9) x (70/51) = -3.35 (negative MoS makes formula meaningless) |
| ZTS | 78 adj | A | 20-25% at $110-115 | R1 complete | QS 78 vs 51, clearly superior quality |
| VEEV | 80 adj | A | ~19% at $150 | R1 complete | QS 80 vs 51, clearly superior quality |
| MORN | -- | -- | ~14% at $154 | R3 complete | Under evaluation |

**Qualitative OS Assessment (since formula breaks with negative MoS):**

When the current position has NEGATIVE MoS (overvalued) and pipeline candidates have POSITIVE MoS (undervalued) with HIGHER quality scores, the opportunity score is effectively infinite. Any capital freed from UHS and redeployed to a Tier A/B candidate with positive MoS is an unambiguous improvement.

**The ~$468 freed from UHS could:**
- Contribute to ROP if it reaches $300 trigger (QS 70, MoS 22%)
- Contribute to ZTS if it reaches $110-115 (QS 78, MoS 20-25%)
- Be held as cash (0% return) which is STILL better than holding overvalued Tier C

**Principio 9 (Quality Gravitation):** UHS is Tier C with 1.5pp ROIC-WACC spread. The portfolio should gravitate toward Tier A compounders. Every euro in UHS is a euro NOT in a quality compounder.

---

### GATE 5: Dead Money?

**RESULT: Not dead money historically (+16.2% gain), but DEAD MONEY going forward.**

The position has appreciated from $201.42 to $234.05 (+16.2%), which is a successful outcome. However:

1. **At $234 vs FV $213, the forward expected return is NEGATIVE.** The stock needs to revert DOWN to fair value.
2. **The EPS growth driving this appreciation (Q3 +53.4%) is peak-cycle.** FY2025 is likely the BEST year. FY2026 faces Medicaid headwinds.
3. **No positive catalyst ahead.** The Feb 25 earnings event is more likely to introduce RISKS (Medicaid guidance) than UPSIDE (what new information could raise FV above $234?).
4. **Even bull case ($276) represents only 18% upside** vs current price. The risk/reward is asymmetric to the downside.

---

### GATE 6: Exit Friction

**RESULT: Friction is NEGLIGIBLE. Strong argument to exit.**

| Component | Value |
|-----------|-------|
| Position size | $468.10 (2 shares x $234.05) |
| Gain | +$65.26 (+16.2%) |
| Tax (estimated, if applicable) | Minimal -- small absolute gain |
| Commission | ~$0 (eToro) |
| Spread | <0.1% (liquid stock, 14.9B market cap) |
| Portfolio impact | ~4% of portfolio freed |
| Total friction | **<0.5%** |

**Friction is negligible.** The $65 gain is small enough that tax impact is minimal. The stock is highly liquid. There is no structural impediment to selling.

---

## 6-GATE SUMMARY

| Gate | Finding | Direction |
|------|---------|-----------|
| Gate 1: Kill Condition | None triggered, but KC#1 and KC#4 APPROACHING | NEUTRAL-NEGATIVE |
| Gate 2: Thesis Valid | DEBILITATED -- 3/4 contra-theses weakened, Medicaid cuts are LAW | **SELL** |
| Gate 3: MoS Current | -9.0% OVERVALUED. Every negative-MoS precedent = SELL | **SELL** |
| Gate 4: Better Opportunity | Pipeline has QS 70-80 candidates with positive MoS. OS is effectively infinite | **SELL** |
| Gate 5: Dead Money | +16.2% historical, but NEGATIVE forward return expected | **SELL** |
| Gate 6: Friction | <0.5%, negligible | **SELL** |

**EXIT Protocol Result: 4/6 gates favor SELL. 1 neutral-negative. 1 negligible friction.**

---

## EARNINGS SCENARIO ANALYSIS (Feb 25-26)

### BEAR SCENARIO (Prob: 35%) -- SELL IMMEDIATELY

**Triggers:**
- FY2026 EPS guidance <$20 (KC#5 TRIGGERED)
- Q4 behavioral health volumes negative or flat
- Management acknowledges material Medicaid revenue loss without mitigation plan
- ROIC approaches WACC

**Expected Price Reaction:** -10% to -15% ($199-$211)
**Action:** SELL AT OPEN on Feb 26. Lock in whatever remains of the +16% gain. Do NOT wait for "recovery."

### BASE SCENARIO (Prob: 45%) -- SELL RECOMMENDED

**Triggers:**
- FY2026 EPS guidance $20-22 (in-line with current expectations)
- Q4 behavioral health volumes +1-2% (modest, not accelerating)
- Management provides generic "monitoring OBBBA impact" commentary
- Price stays near $234 (ABOVE FV)

**Expected Price Reaction:** -3% to +3% ($227-$241)
**Action:** SELL ON THE CALL. The thesis is not invalidated but not strengthened either. The position remains overvalued vs FV $213. Tier C + LOW conviction + negative MoS + structural Medicaid risk = no reason to hold. The +16% gain should be taken.

### BULL SCENARIO (Prob: 20%) -- HOLD ONLY IF CONDITIONS MET

**All three must be true:**
1. FY2026 EPS guidance >$23 (significantly above consensus $22.50)
2. Q4 behavioral health volumes >+3% (genuine acceleration)
3. Management provides QUANTIFIED Medicaid mitigation plan with credible offsets

**If all three met:**
- Implies FV should be raised to $250-260
- MoS at $234 becomes +7-10% (positive but modest)
- HOLD with MEDIUM conviction upgrade
- Set TRIM at $260
- Next review at Q1 2026 earnings

**Expected Price Reaction:** +8% to +15% ($253-$269)

**Honest Assessment:** This scenario requires ALL three conditions. Even one missing (e.g., good guidance but flat volumes) means the thesis remains debilitated. The probability is 20% at best.

---

## PRECEDENT CONSISTENCY CHECK

| Precedent | QS | Tier | MoS | Action | Similarity to UHS |
|-----------|-----|------|-----|--------|-------------------|
| PFE (Feb 7) | 47 | C | -3.2% | SELL | **HIGH** -- Overvalued Tier C, ROIC < WACC, structural headwinds |
| SHEL.L (Feb 6) | 36 | C | -3.5% | SELL | **HIGH** -- Overvalued Tier C, thesis debilitated |
| SAN.PA (Feb 9) | 55 | B low | ~0% | SELL | **MEDIUM** -- Near FV, structural pipeline risk |
| IMB.L (Feb 10) | 54 | C | -14.6% | SELL | **HIGH** -- Overvalued Tier C, undocumented risks |
| TATE.L (Feb 8) | 45 | C | near 0% | SELL | **MEDIUM** -- Tier C near FV |
| **UHS (current)** | **51** | **C** | **-9.0%** | **?** | -- |

**Pattern: Every Tier C position with MoS <= 0% was SOLD.** UHS at -9.0% MoS is MORE overvalued than most of these precedents.

Deviating from this pattern would require a STRONG argument. The only argument is "earnings in 12 days might change things." But:
1. Every scenario except the 20% bull leads to SELL anyway
2. The risk of price DROP on earnings (bear scenario) exceeds the potential gain
3. We have a +16.2% gain to protect
4. The position is tiny ($468) -- the information value of waiting is minimal

---

## RECOMMENDATION

### PRIMARY: SELL BEFORE EARNINGS (Feb 25)

**Rationale (applying Framework v4.0 principles):**

**Principio 5 (QS as Input):** QS 51 Tier C. The tool correctly identifies UHS as a Special Situation with marginal value creation (1.5pp ROIC-WACC spread). This is NOT a business that compounds value.

**Principio 6 (Selling Requires Argument):**
The argument FOR selling:
1. MoS is -9.0% (OVERVALUED). Zero precedent for holding Tier C at negative MoS.
2. Thesis DEBILITATED: 3/4 contra-theses weakened. Medicaid cuts are LAW, not risk.
3. ROIC-WACC spread is only 1.5pp -- one bad quarter away from value destruction.
4. Behavioral volumes stalled (Q1 declined, Q2 +0.4%, Q3 +0.5%). Revenue growth is pricing, not volume.
5. Better opportunities exist: ROP (QS 70), ZTS (QS 78), VEEV (QS 80) in pipeline.
6. +16.2% gain to lock in. Position is small ($468). Friction <0.5%.

The argument AGAINST selling:
1. Earnings in 12 days might produce bull outcome (20% probability).
2. Q3 was exceptional (+53.4% EPS). Q4 could also beat.

**Assessment:** The bull argument requires a 20% probability event to justify holding a Tier C position with negative MoS, debilitated thesis, structural headwinds, and zero precedent for this decision. The argument is insufficient.

**Principio 7 (Consistency):** 5 Tier C positions with MoS <= 0% were all sold (PFE, SHEL.L, A2A.MI, TATE.L, VNA.DE). Holding UHS at -9.0% MoS would be inconsistent without a fundamentally different argument. "Earnings are soon" is not a fundamental difference -- IMB.L was sold at -14.6% MoS without waiting for next earnings.

**Principio 9 (Quality Gravitation):** UHS is Tier C. The portfolio aspires to Tier A. Every euro in UHS is a euro not in a quality compounder. With 48% cash and pipeline candidates at QS 70-80, the opportunity cost is real.

### SELL TARGET: At market open, Feb 14 or Feb 25 (orchestrator's choice of timing)

### CAPITAL REDEPLOYMENT PLAN

~$468 freed ($393 EUR equivalent at current FX). Options:
1. **Hold as cash** -- Portfolio already at 48%. Additional 4% brings to ~52%. Justified by earnings week Feb 23-26 uncertainty.
2. **Contribute to ROP standing order at $300** -- If ROP drops 6.6% to trigger, this capital is ready.
3. **Contribute to ZTS/VEEV** -- When pipeline advances to R4 approval and standing orders are set.

**Recommended:** Hold as cash through Feb 23-26 earnings week. Redeploy per capital deployment framework once earnings clarity emerges on remaining positions (MONY.L, EDEN.PA, VICI, DTE.DE).

---

## VALUE TRAP CHECKLIST (Updated)

| Factor | Status | Change vs v3.0 |
|--------|--------|-----------------|
| Industry in secular decline | NO | Unchanged |
| Technological disruption | NO | Unchanged |
| Management destroying value | NO | Unchanged |
| Balance sheet deteriorating | NO | D/E 0.70, stable |
| Insider selling | NO | Miller family aligned |
| Dividend cut probable | NO | Recently announced |
| Market share loss >2pp | NO | Unchanged |
| ROIC < WACC | **PARTIAL** | 1.5pp spread, fragile |
| FCF negative >2 years | NO | FY2024 $1.1B strong |
| Goodwill >50% equity | **YES** | 58% confirmed |
| Regulatory headwind | **YES** | OBBBA + DOJ/OIG dual |

**Score: 2.5/10 (stable).** Not a classic value trap, but the regulatory and ROIC risks are structural and forward-looking.

---

## POSITION UPDATE FOR THESIS

**If SELL executed:**
- Move thesis to `thesis/archive/UHS/`
- Update `portfolio/history.yaml` with: P&L +16.2%, holding period 23 days (Feb 2 to Feb 25), reason: "EXIT Protocol 4/6 gates SELL. Tier C, MoS -9%, thesis debilitated (Medicaid OBBBA), ROIC barely > WACC, better pipeline opportunities."
- Remove from sector view active dependencies
- Cancel all UHS price monitors and standing orders

---

## META-REFLECTION

### Changes Detected Since Last Review (Feb 10)
- Price increased from $212.94 to $234.05 (+10%) with NO new positive information. This WORSENED the risk/reward.
- Quality scorer tool now shows legacy QS 60 (was 51 in thesis). The profile data shows ROIC-WACC spread of 1.5pp (slightly improved from 1.2pp in thesis, but both are marginal). I continue to assess QS at ~51 Tier C based on the full profile.
- CEO Marc Miller publicly acknowledged OBBBA "simply can't be left as is" -- confirming management sees this as a structural threat they hope will be politically modified.
- Behavioral health volumes confirmed at +0.5% Q3 (not accelerating).

### Incertidumbres
- The QS legacy score (60) differs from thesis (51). The discrepancy comes from the GM premium metric (UHS shows 90% GM which is inflated by how yfinance categorizes hospital revenue vs COGS). The 90% GM is NOT a true gross margin in the manufacturing sense -- it reflects service revenue where most costs are operating expenses, not cost of goods. This inflates the moat score. The thesis QS of 51 is more accurate.
- Q4 behavioral health volumes are unknown. There is a non-trivial probability (20%) that Q4 shows genuine acceleration.
- OBBBA implementation timeline is uncertain. Some states may delay work requirements.

### Sugerencias
1. **Fix quality_scorer.py for hospital/healthcare services companies.** The 90% GM is misleading for hospitals where COGS is not the primary cost category. Operating margin is a better quality signal for this industry.
2. **Add "OBBBA exposure" as a sector-level risk factor in pharma-healthcare.md.** Any hospital operator with >20% Medicaid payer mix should be flagged.
3. **Create pre-earnings EXIT analysis template.** This analysis took significant effort but the structure (6 gates + scenarios + precedent check) should be standardized.

### Alertas para Orchestrator
- **UHS is -9.0% overvalued vs FV. SELL is the clear recommendation.** Waiting for earnings creates asymmetric downside risk.
- **If orchestrator prefers to wait until Feb 25:** Set HARD SELL at any price on Feb 26 unless ALL three bull conditions are met (guide >$23, volumes >+3%, quantified Medicaid mitigation). Partial/mixed results = SELL.
- **Pattern note:** UHS would be the 9th position with ROIC near/below WACC to be exited, and the 6th Tier C with negative MoS to be sold. Both patterns have 100% consistency.

---

**Sources:**
- [UHS Q4 2025 Earnings Date](https://www.stocktitan.net/news/UHS/universal-health-services-inc-announces-date-for-fourth-quarter-2025-c0jxssh3f37l.html)
- [UHS CEO on OBBBA](https://bhbusiness.com/2025/07/29/uhs-ceo-marc-miller-obbba-simply-cant-be-left-as-is/)
- [UHS Q3 2025 Results](https://ir.uhs.com/news-releases/news-release-details/universal-health-services-inc-announces-financial-results-0)
- [OBBBA Healthcare Impact - Consumer Edge](https://www.consumeredge.com/resources/insight-deep-dive/obbba-and-medicaid-cuts-how-the-one-big-beautiful-bill-act-will-reshape-u-s-healthcare-in-2026/)
- [OBBBA Healthcare Changes - AMA](https://www.ama-assn.org/health-care-advocacy/federal-advocacy/4-big-beautiful-bill-changes-will-reshape-care-2026)
- [UHS Analyst Consensus](https://stockanalysis.com/stocks/uhs/forecast/)
- [UHS Behavioral Health Volumes](https://www.nasdaq.com/articles/universal-health-services-uhs-q3-earnings-how-key-metrics-compare-wall-street-estimates)
- quality_scorer.py v4.0, price_checker.py, forward_return.py
- learning/principles.md, learning/decisions_log.yaml, world/current_view.md

---

**Last Updated:** 2026-02-13
